Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Ken K Y Ho in
Google Scholar
PubMed
Search for other papers by Bradley S Miller in
Google Scholar
PubMed
Search for other papers by Ignacio Bergada in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
but may also be triggered by organic causes. To distinguish between transient and persistent GHD in the adolescent patient transitioning into adulthood requires re-testing in the transition phase after the completion of linear growth ( 1 , 2 , 3
Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Victoria, Australia
Department of Endocrinology and Metabolism, BSMMU, Dhaka, Bangladesh
Search for other papers by Sharmin Jahan in
Google Scholar
PubMed
Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Victoria, Australia
Search for other papers by Jun Yang in
Google Scholar
PubMed
Search for other papers by Jinbo Hu in
Google Scholar
PubMed
Search for other papers by Qifu Li in
Google Scholar
PubMed
Search for other papers by Peter J Fuller in
Google Scholar
PubMed
factors ( 17 ). It is important to confirm an elevated ARR with additional testing unless the patient has florid biochemical features of PA including suppressed renin, high aldosterone concentration, and hypokalemia. Indeed, a recent meta-analysis of 31
Search for other papers by Dongyan Han in
Google Scholar
PubMed
Search for other papers by Min Ding in
Google Scholar
PubMed
Search for other papers by Rongli Xie in
Google Scholar
PubMed
Shanghai Center of Thyroid Diseases, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
Search for other papers by Zhengshi Wang in
Google Scholar
PubMed
Search for other papers by Guohui Xiao in
Google Scholar
PubMed
Search for other papers by Xiaohong Wang in
Google Scholar
PubMed
Search for other papers by Lei Dong in
Google Scholar
PubMed
Shanghai Center of Thyroid Diseases, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
Search for other papers by Zhiqiang Yin in
Google Scholar
PubMed
Research Institute of Pancreatic Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai, China
Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China
Search for other papers by Jian Fei in
Google Scholar
PubMed
current diagnostic modalities routinely used for thyroid disorders in China include palpation, ultrasonography, and serum testing of thyroid function. Ultrasonography based on the American Thyroid Association (ATA) risk stratification criteria is a common
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Grethe Å Ueland in
Google Scholar
PubMed
Search for other papers by Thea Grinde in
Google Scholar
PubMed
Department of Medicine, Haukeland University Hospital, Bergen, Norway
K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Search for other papers by Paal Methlie in
Google Scholar
PubMed
Search for other papers by Oskar Kelp in
Google Scholar
PubMed
K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Search for other papers by Kristian Løvås in
Google Scholar
PubMed
Department of Medicine, Haukeland University Hospital, Bergen, Norway
K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Search for other papers by Eystein S Husebye in
Google Scholar
PubMed
therefore recommended that all patients with AI should be assessed for ACS. The most recent international guidelines recommend the 1 mg overnight dexamethasone suppression test (DST) to screen for ACS ( 1 ). This test is not optimal, as the DST has low
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Laura Potasso in
Google Scholar
PubMed
Search for other papers by Julie Refardt in
Google Scholar
PubMed
Search for other papers by Irina Chifu in
Google Scholar
PubMed
Central Laboratory, University Hospital Wuerzburg, Wuerzburg, Germany
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, Germany
Search for other papers by Wiebke Kristin Fenske in
Google Scholar
PubMed
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Mirjam Christ-Crain in
Google Scholar
PubMed
Introduction The hypertonic saline infusion test with continuous infusion of 3% NaCl has recently been put forward as a new test for the diagnosis of diabetes insipidus (DI) ( 1 ). For other indications such as hemorrhagic and septic shock
Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Salford, UK
Search for other papers by Lauren Bell in
Google Scholar
PubMed
Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Salford, UK
Search for other papers by Ann Louise Hunter in
Google Scholar
PubMed
CEDM Centre of Endocrinology, Diabetes & Metabolism, Limassol, Cyprus
Search for other papers by Angelos Kyriacou in
Google Scholar
PubMed
Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Salford, UK
Search for other papers by Annice Mukherjee in
Google Scholar
PubMed
Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Salford, UK
Search for other papers by Akheel A Syed in
Google Scholar
PubMed
triiodothyronine (T3) ( 6 ). Additional diagnostic tests can include imaging (commonly ultrasound and radioisotope uptake study) and thyroid autoantibodies, which can help to distinguish GD from other causes of thyrotoxicosis. The autoimmune production of TSH
Search for other papers by Ramjan Sanas Mohamed in
Google Scholar
PubMed
Search for other papers by Biyaser Abuelgasim in
Google Scholar
PubMed
Search for other papers by Sally Barker in
Google Scholar
PubMed
Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Niamh M Martin in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Karim Meeran in
Google Scholar
PubMed
Search for other papers by Emma L Williams in
Google Scholar
PubMed
Search for other papers by Sarah Darch in
Google Scholar
PubMed
Search for other papers by Whitlock Matthew in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Tricia Tan in
Google Scholar
PubMed
Search for other papers by Florian Wernig in
Google Scholar
PubMed
Introduction Cushing’s syndrome (CS) is caused by prolonged and inappropriate exposure of tissues to glucocorticoids ( 1 ). Endogenous CS often poses considerable diagnostic challenges. Most guidelines recommend two different tests to screen
Search for other papers by Danielle Christine Maria van der Kaay in
Google Scholar
PubMed
Search for other papers by Anne Rochtus in
Google Scholar
PubMed
Search for other papers by Gerhard Binder in
Google Scholar
PubMed
Search for other papers by Ingo Kurth in
Google Scholar
PubMed
Search for other papers by Dirk Prawitt in
Google Scholar
PubMed
Search for other papers by Irène Netchine in
Google Scholar
PubMed
Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Anita C S Hokken-Koelega in
Google Scholar
PubMed
Search for other papers by Miriam Elbracht in
Google Scholar
PubMed
Search for other papers by Thomas Eggermann in
Google Scholar
PubMed
for SRS testing) SGA, postnatal growth retardation, short stature, prominent forehead, feeding difficulties, boday asymmetry, café-au-lait spots, Burkitt lymphome at age 9 years. Normal psychomotoric development. (referred for SRS testing
Department of Endocrinology, Department of Public Health, Department of Cancer Research and Molecular Medicine, Department of Medical Biochemistry, St Olavs Hospital, Trondheim University Hospital, P O Box 3250 Sluppen, N-7006 Trondheim, Norway
Search for other papers by Bjørn O Åsvold in
Google Scholar
PubMed
Department of Endocrinology, Department of Public Health, Department of Cancer Research and Molecular Medicine, Department of Medical Biochemistry, St Olavs Hospital, Trondheim University Hospital, P O Box 3250 Sluppen, N-7006 Trondheim, Norway
Search for other papers by Valdemar Grill in
Google Scholar
PubMed
Search for other papers by Ketil Thorstensen in
Google Scholar
PubMed
Department of Endocrinology, Department of Public Health, Department of Cancer Research and Molecular Medicine, Department of Medical Biochemistry, St Olavs Hospital, Trondheim University Hospital, P O Box 3250 Sluppen, N-7006 Trondheim, Norway
Search for other papers by Marit R Bjørgaas in
Google Scholar
PubMed
Introduction The 1 mg overnight dexamethasone suppression test (DST) is a common initial test for endogenous Cushing's syndrome (1) . The principle of the test is that dexamethasone will suppress ACTH and cortisol secretion in healthy individuals
Search for other papers by Jose M Garcia in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Search for other papers by Vera Popovic in
Google Scholar
PubMed
Search for other papers by Anton Luger in
Google Scholar
PubMed
Search for other papers by Christian J Strasburger in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Ronald Swerdloff in
Google Scholar
PubMed
Search for other papers by Christina Wang in
Google Scholar
PubMed
Search for other papers by Rosa Rosanna Fleming in
Google Scholar
PubMed
Search for other papers by Fredric Cohen in
Google Scholar
PubMed
Search for other papers by Nicola Ammer in
Google Scholar
PubMed
Search for other papers by Gilbert Mueller in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Frank Strobl in
Google Scholar
PubMed
Search for other papers by Vlady Ostrow in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
on diagnosis and disease progression ( 17 ). Thus, except in patients with panhypopituitarism and low insulin-like growth factor I (IGF-I) levels, the diagnosis of AGHD often requires confirmation using a provocative GH stimulation test (GHST) ( 18